News & Updates

Postop opioids up risks of persistent opioid use, emergency visits, readmission and all-cause mortality

30 Sep 2023 by

A large retrospective cohort study by the University of Hong Kong (HKU) finds that postoperative prescription of opioids is associated with increased risks of new persistent opioid use, 30-day emergency department visits, 30-day readmission, and 30-day all-cause mortality.

Postop opioids up risks of persistent opioid use, emergency visits, readmission and all-cause mortality

30 Sep 2023

Pretreatment serum CEA level predicts survival in NSCLC

29 Sep 2023

Pretreatment level of serum carcinoembryonic antigen (CEA) is independently associated with overall and disease-free survival among patients with nonsmall cell lung cancer (NSCLC), reports a study. The same marker is also used for the prognosis of patients with the same pathologic stages.

Pretreatment serum CEA level predicts survival in NSCLC

29 Sep 2023

Noninvasive inverted urothelial papillary tumour tied to low recurrence, better outcomes

29 Sep 2023

Noninvasive urothelial papillary lesions of the bladder with an inverted growth pattern appear to have a low chance of recurrence and are associated with better outcomes, suggests a study.

Noninvasive inverted urothelial papillary tumour tied to low recurrence, better outcomes

29 Sep 2023

Nonerosive GERD patients not prone to develop esophageal adenocarcinoma

28 Sep 2023 by

Patients with nonerosive gastroesophageal reflux disease (GERD) show no higher incidence of esophageal adenocarcinoma (EAC) when compared with the general population, according to a study.

Nonerosive GERD patients not prone to develop esophageal adenocarcinoma

28 Sep 2023

FIT helps assess risk of advanced neoplasia before surveillance colonoscopy

27 Sep 2023

Faecal immunochemical test (FIT) appears to provide useful information regarding a patient’s risk of advanced neoplasia and subsequently help physicians decide which patients should be prioritized for a colonoscopy, according to a study.

FIT helps assess risk of advanced neoplasia before surveillance colonoscopy

27 Sep 2023

Atezolizumab-chemo confers durable survival benefit in ES-SCLC

27 Sep 2023 by

In the merged analysis of the IMpower133 trial and IMbrella A open-label extension study, the combination of the PD-L1 inhibitor atezolizumab and a chemotherapy regimen comprising carboplatin and etoposide (CP/ET) demonstrated potential for survival benefit of up to 5 years in patients with extensive stage-small-cell lung cancer (ES-SCLC).

Atezolizumab-chemo confers durable survival benefit in ES-SCLC

27 Sep 2023

No benefit to adding subablative multisite SBRT to ICI monotherapy for advanced solid tumours

26 Sep 2023

Adding subablative stereotactic body radiotherapy (SBRT) concurrently to immune checkpoint inhibitor (ICI) monotherapy does little to improve survival outcomes in patients with advanced solid tumours, as shown in the phase II CHEERS trial.

No benefit to adding subablative multisite SBRT to ICI monotherapy for advanced solid tumours

26 Sep 2023

Antidepressant use among HCC patients linked to lower risk of death

22 Sep 2023

For patients with hepatocellular carcinoma (HCC), the use of antidepressants after diagnosis may signal increased overall and cancer-specific survival, according to a study.